The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Recent updates from ECHELON-1 and implications for the treatment of HL
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of recent updates in the treatment of Hodgkin lymphoma (HL), drawing focus on the recent ECHELON-1 (NCT01712490) trial investigating the use of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with HL. Dr Collins briefly discusses some of the results obtained in this trial, including the recent overall survival (OS) benefit which has been reported. Although data still needs to be presented on the relevance of this OS benefit, Dr Collins discusses the exciting implications that these findings may have for older patients who are unable to withstand the intensity of the commonly used escalated BEACOPP approach. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honoraria: Roche, Takeda, Gilead, Pfizer, MSD, Celleron, ADC Therapeutics, Incyte, Beigene. Research funding: BMS, MSD, Celleron, Amgen, BMS
